Strategies Emerge to Mitigate Post-GLP-1 Weight Regain

Glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated substantial efficacy in weight reduction for individuals with obesity or overweight with comorbidities.¹ However, a significant clinical challenge arises upon discontinuation of these agents: a substantial proportion of the initial weight loss is typically regained.² This regain often approaches or exceeds two-thirds of the weight lost during active treatment within 12 months of cessation, underscoring the chronic nature of obesity and the need for sustained management strategies.³ The physiological mechanisms contributing to this regain include a return to baseline appetite regulation, increased hunger, and decreased satiety, which were modulated by GLP-1 agonism.⁴

Addressing this post-cessation weight regain is critical for optimising long-term patient outcomes and maximising the clinical utility of GLP-1 receptor agonists. The current clinical dilemma is how to transition patients from intensive weight loss phases to effective weight maintenance, particularly given the chronic disease model of obesity.⁵

Emerging Strategies for Weight Maintenance

Several strategies are being investigated to mitigate post-GLP-1 weight regain. One primary approach involves the continuation of pharmacological therapy, albeit potentially at a lower dose or with different agents. Studies have shown that patients who continue GLP-1 receptor agonist therapy, even at reduced doses, maintain a greater proportion of their weight loss compared to those who discontinue treatment entirely.⁶ For example, in trials involving semaglutide, patients who continued treatment maintained an average weight loss of approximately 15% from baseline, whereas those switched to placebo regained approximately two-thirds of their lost weight within one year.⁷ This suggests that obesity management, similar to other chronic conditions like hypertension or type 2 diabetes, often requires ongoing pharmacological intervention.

Combination therapies represent another emerging solution. The co-administration of GLP-1 receptor agonists with other agents that target different pathways involved in appetite regulation and energy expenditure is under investigation. For instance, dual agonists targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, such as tirzepatide, have shown superior weight loss efficacy compared to GLP-1 monotherapy.⁸ The sustained use of such dual agonists may offer a more robust mechanism for long-term weight maintenance. Additionally, combinations with amylin analogues or other novel agents are being explored to enhance satiety and metabolic control.⁹

Beyond pharmacological interventions, structured lifestyle modification programs are being evaluated as a complementary or alternative strategy for weight maintenance post-GLP-1 therapy. These programs typically involve intensive dietary counselling, increased physical activity, and behavioural therapy. While lifestyle interventions alone may not fully prevent weight regain after the cessation of highly effective pharmacological agents, they can provide a supportive framework.¹⁰ The integration of digital health tools and remote monitoring may also enhance adherence and provide ongoing support, potentially improving long-term outcomes.¹¹

The current evidence base, while growing, highlights the necessity of a chronic disease management approach to obesity. Discontinuation of effective anti-obesity medications without a robust maintenance plan is associated with predictable weight regain. Further research is required to delineate optimal dosing strategies for long-term GLP-1 use, identify patient subgroups most likely to benefit from specific maintenance interventions, and evaluate the cost-effectiveness of sustained pharmacological therapy versus intensive lifestyle programs. The long-term safety and tolerability profiles of extended GLP-1 agonism and novel combination therapies also warrant continued surveillance.¹²